drugset / Trial / NCT00213291

Darbepoetin Treatment of Anemia in Children With Chronic Renal Failure

NCT00213291

Phase 3 Completed 40 enrolled The Hospital for Sick Children
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a study to determine the safety and effectiveness of Darbepoetin (Aranesp) given every 14 to 28 days to treat low red blood cells in children with chronic kidney failure.

Timeline

Start
2005-04
Primary completion
2005-09
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Darbepoetin alfa Protein / enzyme biologic 0.9 ug/kg Subcutaneous
Subject Darbepoetin alfa Protein / enzyme biologic 20 ug Subcutaneous